TESARO Inc (NASDAQ:TSRO) SVP Orlando Oliveira sold 3,000 shares of the stock in a transaction on Thursday, March 8th. The shares were sold at an average price of $69.88, for a total transaction of $209,640.00. Following the completion of the transaction, the senior vice president now directly owns 9,076 shares in the company, valued at $634,230.88. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Shares of TESARO Inc (TSRO) opened at $68.12 on Monday. The firm has a market cap of $3,700.00, a price-to-earnings ratio of -7.42 and a beta of 1.40. The company has a debt-to-equity ratio of 1.75, a quick ratio of 4.35 and a current ratio of 4.74. TESARO Inc has a 52 week low of $52.20 and a 52 week high of $176.04.
TESARO (NASDAQ:TSRO) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($3.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.39) by ($0.96). The business had revenue of $48.02 million for the quarter, compared to analyst estimates of $51.78 million. TESARO had a negative return on equity of 126.44% and a negative net margin of 222.15%. analysts forecast that TESARO Inc will post -9.54 earnings per share for the current year.
A number of research firms recently commented on TSRO. BidaskClub raised shares of TESARO from a “strong sell” rating to a “sell” rating in a research report on Tuesday, March 6th. Morgan Stanley dropped their target price on shares of TESARO from $156.00 to $146.00 and set an “overweight” rating on the stock in a research report on Thursday, March 1st. ValuEngine raised shares of TESARO from a “sell” rating to a “hold” rating in a research report on Friday, March 2nd. Credit Suisse Group reaffirmed an “in-line” rating and issued a $141.00 target price (down from $150.00) on shares of TESARO in a research report on Wednesday, February 28th. Finally, Wells Fargo & Co reaffirmed an “outperform” rating and issued a $122.00 target price (down from $224.00) on shares of TESARO in a research report on Wednesday, February 28th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. TESARO has a consensus rating of “Buy” and an average target price of $133.39.
ILLEGAL ACTIVITY WARNING: “TESARO Inc (TSRO) SVP Sells $209,640.00 in Stock” was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://baseballnewssource.com/2018/03/12/tesaro-inc-tsro-svp-sells-209640-00-in-stock/2016368.html.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.